Skip to content
PubMed This is a summary of 13 peer-reviewed journal articles Updated
Genetics

How Do I Read My FSHD Genetic Test Results?

At a Glance

To develop FSHD, your genetic test must show two things on chromosome 4: a shortened D4Z4 repeat chain (usually 1 to 10 repeats) and a 4qA allele. Together, this shortened genetic lock and stabilizer ending allow the toxic DUX4 gene to turn on and damage muscle cells.

When you read your Facioscapulohumeral dystrophy (FSHD) genetic test report, it might look like a confusing mix of letters and numbers. In plain English, this test is looking for a specific genetic combination that accidentally “unlocks” a gene called DUX4. This gene is normally permanently turned off in adult muscles, but when it is turned on, it produces a protein that is toxic to muscle cells [1][2]. To determine if this gene is active, the test measures two main things: the size of the genetic “lock” keeping the gene shut (measured in D4Z4 repeats), and the presence of a genetic stabilizer called 4qA [3].

Reading the Report: Two Copies of Every Gene

Because you inherit one set of chromosomes from each parent, your report will show results for two copies of chromosome 4. You only need one copy with a shortened lock and a 4qA stabilizer to develop FSHD. In medical terms, this is called autosomal dominant inheritance. This means a typical FSHD result will show one normal allele (for example, 35 repeats with 4qB) and one affected allele (for example, 5 repeats with 4qA) [4].

Note: Your report may also list D4Z4 repeats for Chromosome 10. Do not panic if you see a “contraction” on Chromosome 10. These repeats do not have the ability to make the toxic DUX4 protein, so contractions here are harmless and do not cause FSHD [4].

The Genetic “Lock”: D4Z4 Repeats at 4q35

Your DNA contains repeating sequences of genetic code near the end of chromosome 4, specifically in an area called 4q35 [3]. These sequences are called D4Z4 repeats. Think of this section of DNA as a heavy door with a chain lock that keeps the toxic DUX4 gene safely closed off [3].

The test report will provide a number (often called “repeat units” or “RUs”) indicating how many D4Z4 links you have on each of your two copies:

  • Usually Normal Range (More than 20 repeats): In people without FSHD, this chain is long enough to keep the door firmly shut and the DUX4 gene turned off [4][5].
  • Abnormal Range (1 to 10 repeats): If the chain is shortened (called a contraction) to between 1 and 10 repeats, the lock is too small to work properly. This allows the door to swing open, causing the most common form of the condition, known as FSHD1 [5][4].
  • Intermediate Zone (11 to 20 repeats): This number of repeats is generally considered normal, but in some individuals, it can lead to FSHD2 (explained below) [4].

A note on severity: Research shows there is a statistical trend where a very low number of repeats (such as 1 to 3) is associated with symptoms appearing earlier in life [6][7]. However, FSHD is highly variable even within the same family. Your repeat number does not perfectly predict your individual disease course or severity.

The Genetic “Stabilizer”: Why 4qA Matters

Having a shortened D4Z4 chain at 4q35 is only half of the equation. For the DUX4 gene to actually produce the toxic muscle protein, it needs a specific genetic “ending” attached to it, which acts as a stabilizer. This ending is known as the 4qA allele (or 4qA haplotype) [8][3].

  • 4qA (Permissive): This version of the gene includes the stabilizing instructions. If you have the 4qA ending and a shortened D4Z4 chain, the toxic DUX4 protein can be produced and survive in the muscles, leading to FSHD [9][3].
  • 4qB (Non-permissive): This is a different version of the ending. If a person has 4qB instead of 4qA, the DUX4 instructions quickly break down and are harmlessly cleared away by the body before any toxic protein is made. Even if someone has a shortened D4Z4 chain (1 to 10 repeats), they will generally not develop FSHD if they only have the 4qB ending [3].

What if my repeats are in the intermediate zone? (FSHD2)

If your report shows a D4Z4 repeat number of 11 to 20, but you still have FSHD symptoms and the 4qA ending, you may have FSHD2 [4].

In FSHD2, the D4Z4 chain is long enough, but the actual physical “key” that tightens the lock is broken. This is most often caused by a mutation in a different gene called SMCHD1 [10][11]. The SMCHD1 protein normally helps pack the DNA tightly to keep DUX4 hidden. When it is mutated, the DNA stays loose and relaxed, allowing the DUX4 gene to turn on despite the normal-length chain [10]. While the genetic cause is slightly different, the end result—muscle damage from the DUX4 protein—is the same in both FSHD1 and FSHD2 [12][13].

Putting Your Results Together

When reviewing your test results with your care team, look for these two crucial pieces of information on chromosome 4:

  1. The number of D4Z4 repeats: Is one of the alleles between 1 and 10 (pointing to FSHD1)?
  2. The 4q status for that allele: Does it say 4qA (which allows the condition to develop)?

Understanding these components can help you and your doctor better predict your care needs. Because genetics can be complicated, it is highly recommended to review these results with a certified genetic counselor, especially before discussing testing with family members.

Common questions in this guide

What does a D4Z4 contraction mean on my FSHD test?
A D4Z4 contraction means the genetic chain that normally keeps the DUX4 gene turned off is shortened. If you have a contraction of 1 to 10 repeats along with the 4qA ending, the gene can turn on and cause FSHD.
What is the difference between the 4qA and 4qB alleles?
The 4qA allele acts as a genetic stabilizer that allows the toxic DUX4 protein to survive in your muscles, causing FSHD. The 4qB allele does not have this stabilizer, so even with a shortened D4Z4 chain, the toxic protein is harmlessly cleared away without causing the disease.
Does the number of D4Z4 repeats predict how severe my FSHD will be?
While there is a statistical trend showing that a very low number of repeats (1 to 3) is associated with symptoms appearing earlier in life, FSHD is highly variable. Your exact repeat number cannot perfectly predict how severe your individual symptoms will be or how they will progress.
What is FSHD2 and how is it diagnosed?
FSHD2 occurs when a person has the 4qA ending and a normal D4Z4 repeat number of 11 to 20, but still develops symptoms. It is usually caused by a mutation in a different gene called SMCHD1, which fails to keep the DUX4 gene properly hidden.
Do contractions on Chromosome 10 cause FSHD?
No. While your test report may show D4Z4 repeat contractions on Chromosome 10, these repeats cannot produce the toxic DUX4 protein. Contractions on this chromosome are harmless and do not cause Facioscapulohumeral dystrophy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific D4Z4 repeat number, what might that indicate about how my symptoms could progress over time?
  2. 2.Does my report show if I have FSHD1 or FSHD2, and does this change my options for symptom management or future clinical trials?
  3. 3.What does my specific autosomal dominant result mean for the likelihood of my children or siblings having the condition?
  4. 4.Is there a need for any additional genetic testing (like checking for an SMCHD1 mutation) based on these results?
  5. 5.Can you refer me to a genetic counselor to help me and my family better understand the implications of this report?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (13)
  1. 1

    Meta-analysis towards FSHD reveals misregulation of neuromuscular junction, nuclear envelope, and spliceosome.

    Schätzl T, Todorow V, Kaiser L, et al.

    Communications biology 2024; (7(1)):640 doi:10.1038/s42003-024-06325-z.

    PMID: 38796645
  2. 2

    Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.

    Bittel AJ, Sreetama SC, Bittel DC, et al.

    International journal of molecular sciences 2020; (21(15)) doi:10.3390/ijms21155575.

    PMID: 32759720
  3. 3

    Inflammatory facioscapulohumeral muscular dystrophy type 2 in 18p deletion syndrome.

    Renard D, Taieb G, Garibaldi M, et al.

    American journal of medical genetics. Part A 2018; (176(8)):1760-1763 doi:10.1002/ajmg.a.38843.

    PMID: 30055030
  4. 4

    CLIA Laboratory Testing for Facioscapulohumeral Dystrophy: A Retrospective Analysis.

    Rieken A, Bossler AD, Mathews KD, Moore SA

    Neurology 2021; (96(7)):e1054-e1062 doi:10.1212/WNL.0000000000011412.

    PMID: 33443126
  5. 5

    FSHD1 and FSHD2 form a disease continuum.

    Sacconi S, Briand-Suleau A, Gros M, et al.

    Neurology 2019; (92(19)):e2273-e2285 doi:10.1212/WNL.0000000000007456.

    PMID: 30979860
  6. 6

    FSHD1 Diagnosis in a Russian Population Using a qPCR-Based Approach.

    Zernov NV, Guskova AA, Skoblov MY

    Diagnostics (Basel, Switzerland) 2021; (11(6)) doi:10.3390/diagnostics11060982.

    PMID: 34071558
  7. 7

    Association of 4qA-Specific Distal D4Z4 Hypomethylation With Disease Severity and Progression in Facioscapulohumeral Muscular Dystrophy.

    Zheng F, Qiu L, Chen L, et al.

    Neurology 2023; (101(3)):e225-e237 doi:10.1212/WNL.0000000000207418.

    PMID: 37225433
  8. 8

    A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.

    Gatica LV, Rosa AL

    Neuromuscular disorders : NMD 2016; (26(12)):844-852 doi:10.1016/j.nmd.2016.09.015.

    PMID: 27816329
  9. 9

    Analyzing Copy Number Variation Using Pulsed-Field Gel Electrophoresis: Providing a Genetic Diagnosis for FSHD1.

    Lemmers RJ

    Methods in molecular biology (Clifton, N.J.) 2017; (1492()):107-125 doi:10.1007/978-1-4939-6442-0_7.

    PMID: 27822859
  10. 10

    Many faces of SMCHD1.

    Wilkie AO

    Nature genetics 2017; (49(2)):176-178 doi:10.1038/ng.3776.

    PMID: 28138148
  11. 11

    SMCHD1 has separable roles in chromatin architecture and gene silencing that could be targeted in disease.

    Tapia Del Fierro A, den Hamer B, Benetti N, et al.

    Nature communications 2023; (14(1)):5466 doi:10.1038/s41467-023-40992-6.

    PMID: 37749075
  12. 12

    Leg Muscle Involvement in Facioscapulohumeral Muscular Dystrophy: Comparison between Facioscapulohumeral Muscular Dystrophy Types 1 and 2.

    Mair D, Huegens-Penzel M, Kress W, et al.

    European neurology 2017; (77(1-2)):32-39 doi:10.1159/000452763.

    PMID: 27855411
  13. 13

    Best practice guidelines on genetic diagnostics of facioscapulohumeral muscular dystrophy: Update of the 2012 guidelines.

    Giardina E, Camaño P, Burton-Jones S, et al.

    Clinical genetics 2024; (106(1)):13-26 doi:10.1111/cge.14533.

    PMID: 38685133

This page explains FSHD genetic testing terms for educational purposes only. Always consult a certified genetic counselor or neurologist to interpret your specific results and understand what they mean for your family.

Get notified when new evidence is published on Facioscapulohumeral dystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.